A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women

Trial Profile

A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs ADXS Dual (Primary) ; Nivolumab (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Advaxis; Bristol-Myers Squibb
  • Most Recent Events

    • 11 Sep 2017 According to an Advaxis media release, this trial will be initiated in 1H 2018.
    • 13 Jun 2017 According to an Advaxis media release, this study has been previewed at annual Investor & Analyst Day.
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top